Vir Biotechnology (VIR) Q1 Loss Deepens Bearish Narrative On Path To Profitability

Vir Biotechnology (VIR) opened Q1 2026 with essentially flat total revenue at about US$0 million and a basic EPS loss of US$0.85, alongside net income excluding extra items of a US$125.7 million loss. This put the latest quarterly performance firmly in loss making territory. Over recent periods the company has seen quarterly revenue move from US$12.4 million in Q4 2024 to US$3.0 million in Q1 2025, US$1.2 million in Q2 2025, US$0.2 million in Q3 2025, US$64.1 million in Q4 2025 and back to roughly US$0 million in Q1 2026. Over the same stretch, basic EPS swung between losses of US$0.76 and US$1.17 per quarter. For investors, these results keep the focus on how quickly revenue growth might eventually support more efficient margins and help narrow ongoing losses.

See our full analysis for Vir Biotechnology.

With the latest numbers on the table, the next step is to compare these results with the widely followed narratives around Vir, to see where the growth story aligns with the data and where the margin profile raises fresh questions.

See what the community is saying about Vir Biotechnology

TTM losses of US$442.7 million keep profitability distant

• Over the last twelve months, Vir recorded total revenue of US$65.5 million alongside a net loss excluding extra items of US$442.7 million and basic EPS of US$3.14 in losses, so the business is still firmly in loss making territory despite revenue on a trailing basis.
• Consensus narrative points to cost control helping over time. However, the trailing twelve month loss compares with quarterly net losses that have ranged between about US$42.9 million and US$163.1 million since Q4 2024, which keeps the focus on whether expense reductions can meaningfully narrow losses.
  • Analysts expect Vir to remain unprofitable over at least the next three years, while trailing losses have increased at roughly 40% per year over the past five years, so the recent Q1 2026 loss of US$125.7 million sits within a wider pattern of heavy spending.
  • Even with forecast revenue growth of 17.8% per year, margins are currently negative and there is no forecasted path to profitability in that window, which tests the idea that cost restructuring alone can shift earnings quickly.

P/S of 22.8x prices in strong growth

• The stock trades on a P/S of 22.8x, which is higher than the US Biotechs industry average of 10.9x but below the peer group average of 31.1x, so investors are already paying a premium relative to the broader industry for Vir’s US$65.5 million of trailing twelve month revenue.
• Bulls point to growth potential to justify this premium, yet the current loss profile adds tension to that view.
  • Revenue is forecast to grow around 17.8% per year, above the cited US market benchmark of 11.4%, which supports the bullish argument that Vir could grow faster than many companies if it hits those revenue targets.
  • At the same time, analysts are not forecasting profitability in the next three years and trailing losses have grown at about 40% per year over five years, so the premium P/S ratio rests mainly on growth expectations rather than current earnings support.

Investors who want to see how that optimistic view translates into detailed assumptions around revenue, margins and future earnings can go straight to the 🐂 Vir Biotechnology Bull Case.

Shareholder dilution and volatile trading add risk to US$9.27 stock

• At a current share price of US$9.27, recent analysis highlights that shareholders have faced dilution over the past year and that the stock has been volatile versus the wider US market over the past three months, which matters when losses are still running at US$442.7 million over the last twelve months.
• Bears point to these balance sheet and trading factors as reasons to be cautious, and the reported figures line up with several of those concerns.
  • With ongoing net losses each quarter, including US$125.7 million in Q1 2026 and no forecasted profitability in the next three years, any further funding needs could mean additional dilution on top of what has already occurred.
  • Short term share price swings, when combined with a P/S of 22.8x and continued losses, mean investors are exposed both to business risk from unprofitable operations and market risk from sharper price moves than the broader US market.

If you want to see how more cautious investors frame those risks around trial timelines, losses and future funding needs, take a look at the 🐻 Vir Biotechnology Bear Case.

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Vir Biotechnology on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

Sentiment around Vir is clearly mixed, with meaningful risks on one side and potential rewards on the other. It makes sense to look through the data yourself, weigh what matters most, and then check the 1 key reward and 3 important warning signs

See What Else Is Out There

Vir is still posting sizeable losses, carries a premium P/S of 22.8x, and faces dilution and volatility risks while profitability remains distant.

If that mix of ongoing losses and share price swings feels uncomfortable, it makes sense to look at 72 resilient stocks with low risk scores today and compare steadier options side by side.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com